PE20191240A1 - Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios - Google Patents

Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios

Info

Publication number
PE20191240A1
PE20191240A1 PE2019001285A PE2019001285A PE20191240A1 PE 20191240 A1 PE20191240 A1 PE 20191240A1 PE 2019001285 A PE2019001285 A PE 2019001285A PE 2019001285 A PE2019001285 A PE 2019001285A PE 20191240 A1 PE20191240 A1 PE 20191240A1
Authority
PE
Peru
Prior art keywords
task
respiratory disorders
treatment
forms
pharmaceutical administration
Prior art date
Application number
PE2019001285A
Other languages
English (en)
Inventor
Johanna Anlahr
Moritz Beck-Broichsitter
Janine Nicolai
Martina Delbeck
Michael Hahn
Udo Albus
Doris Gehring
Bjorn Rosenstein
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16205688.1A external-priority patent/EP3338764A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20191240A1 publication Critical patent/PE20191240A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a una formulacion farmaceutica estable para aplicacion industrial nasal o faringea que contiene una cantidad terapeutica eficaz de un inhibidor del canal TASK-1 y/o TASK-3, una sal farmaceuticamente aceptable, solvato, entre otros; en 1% al 100% p/v de glicerol y opcionalmente un adyuvante; en condiciones de pH de 4 a 8. En donde el inhibidor es preferiblemente (4-{[2-(4-clorofenil)imidazo[1,2-a]piridina-3-il]metil}piperazin-1-il)(6-metoxi-piridina-2-il)metanona o un hidrato, solvato, sal farmaceuticamente aceptable. Tambien se refiere a su uso para el tratamiento y/o prevencion de trastornos respiratorios, incluyendo trastornos respiratorios relacionados con el sueno, tales como la apnea obstructiva y la apnea central del sueno y el ronquido.
PE2019001285A 2016-12-21 2017-12-13 Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios PE20191240A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205688.1A EP3338764A1 (de) 2016-12-21 2016-12-21 Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
EP17157805 2017-02-24

Publications (1)

Publication Number Publication Date
PE20191240A1 true PE20191240A1 (es) 2019-09-16

Family

ID=60857052

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001285A PE20191240A1 (es) 2016-12-21 2017-12-13 Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios

Country Status (23)

Country Link
US (1) US20200093737A1 (es)
EP (1) EP3558380A1 (es)
JP (1) JP2020502215A (es)
KR (1) KR20190099245A (es)
CN (1) CN110290809A (es)
AU (1) AU2017379245A1 (es)
BR (1) BR112019012836A2 (es)
CA (1) CA3047426A1 (es)
CL (1) CL2019001726A1 (es)
CO (1) CO2019006642A2 (es)
CR (1) CR20190299A (es)
CU (1) CU20190063A7 (es)
DO (1) DOP2019000172A (es)
EC (1) ECSP19044577A (es)
IL (1) IL267503A (es)
JO (1) JOP20190148A1 (es)
MA (1) MA47074A (es)
MX (1) MX2019007619A (es)
PE (1) PE20191240A1 (es)
PH (1) PH12019501458A1 (es)
TW (1) TW201834653A (es)
UY (1) UY37541A (es)
WO (1) WO2018114501A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3386979B1 (de) 2015-12-10 2020-07-29 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
ES2966457T3 (es) 2018-06-18 2024-04-22 Janssen Pharmaceutica Nv Derivados de pirazol como inhibidores de MALT1
JOP20210121A1 (ar) 2018-11-27 2023-01-30 Bayer Ag عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة task-1 و task-3، واستخدامها في علاج اضطراب التنفس
EP4176880A1 (en) * 2020-07-01 2023-05-10 National Cancer Center Pharmaceutical composition for preventing or treating cancer comprising 3-ketoacyl-coa thiolase inhibitor and carnitine acylcarnitine carrier inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP2012758A2 (en) * 2006-04-27 2009-01-14 Sanofi-Aventis Deutschland GmbH Inhibitors of the task-1 and task-3 ion channel
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN106977530A (zh) 2010-07-09 2017-07-25 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
US9132243B2 (en) 2010-07-23 2015-09-15 Tannermedico A/S Method of administering a substance to the throat
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
CN103877288B (zh) * 2014-04-16 2016-01-20 广西信业生物技术有限公司 一种壳聚糖鼻咽生物医用膜及其制备方法

Also Published As

Publication number Publication date
AU2017379245A1 (en) 2019-07-11
CA3047426A1 (en) 2018-06-28
IL267503A (en) 2019-08-29
CN110290809A (zh) 2019-09-27
CR20190299A (es) 2019-09-04
DOP2019000172A (es) 2019-07-15
BR112019012836A2 (pt) 2019-12-17
US20200093737A1 (en) 2020-03-26
UY37541A (es) 2018-07-31
CO2019006642A2 (es) 2019-09-18
PH12019501458A1 (en) 2020-06-01
CL2019001726A1 (es) 2019-11-29
WO2018114501A1 (de) 2018-06-28
MX2019007619A (es) 2019-09-06
ECSP19044577A (es) 2019-06-30
KR20190099245A (ko) 2019-08-26
JOP20190148A1 (ar) 2019-06-18
EP3558380A1 (de) 2019-10-30
JP2020502215A (ja) 2020-01-23
TW201834653A (zh) 2018-10-01
MA47074A (fr) 2021-04-14
CU20190063A7 (es) 2020-02-04

Similar Documents

Publication Publication Date Title
PE20191240A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
PE20191241A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015018168A2 (pt) inibidores de rock suaves
NZ630166A (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
BR112014004435A2 (pt) inibidores de quinase rock
EA201990664A1 (ru) Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
BR112015009504A2 (pt) inibidores de rock
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
MX366353B (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
EA201991540A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания
NZ713490A (en) Oral suspension for treating eosinophilic esophagitis
EA201891911A1 (ru) Применение тамоксифена для лечения кистозного фиброза у пациентов обоих полов
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos